

TRACTATENBLAD

VAN HET

KONINKRIJK DER NEDERLANDEN

JAARGANG 2022 Nr. 3

A. TITEL

*Overeenkomst ter bestrijding van doping (met Bijlage);
Straatsburg, 16 november 1989*

Voor een overzicht van de verdragsgegevens, zie verdragsnummer 003898 in de Verdragenbank.

B. TEKST

De Commissie van Toezicht heeft op 6 december 2021, op grond van artikel 11, eerste lid, onder b, van de Overeenkomst, een wijziging van de Bijlage aangenomen. De Engelse tekst¹⁾ van de wijziging luidt als volgt:

Anti-doping convention (ETS no. 135) – amendment to the appendix

(approved by the 54th Monitoring Group by written procedure under Article 11.1.b of the Convention on 6 December 2021

The 2022 Prohibited List

– World Anti-Doping Code

Date of entry into force: 1 January 2022

Introduction

The *Prohibited List* is a mandatory *International Standard* as part of the World Anti-Doping Program.

The *List* is updated annually following an extensive consultation process facilitated by WADA. The effective date of the *List* is 01 January 2022.

The official text of the *Prohibited List* shall be maintained by WADA and shall be published in English and French. In the event of any conflict between the English and French versions, the English version shall prevail.

Below are some terms used in this *List of Prohibited Substances* and *Prohibited Methods*.

Prohibited In-Competition

Subject to a different period having been approved by WADA for a given sport, the *In-Competition* period shall in principle be the period commencing just before midnight (at 11:59 p.m.) on the day before a *Competition* in which the *Athlete* is scheduled to participate until the end of the *Competition* and the *Sample* collection process.

Prohibited at all times

This means that the substance or method is prohibited *In-* and *Out-of-Competition* as defined in the *Code*.

¹⁾ De Franse tekst is niet opgenomen.

Specified and non-Specified

As per Article 4.2.2 of the *World Anti-Doping Code*, "for purposes of the application of Article 10, all *Prohibited Substances* shall be *Specified Substances* except as identified on the *Prohibited List*. No *Prohibited Method* shall be a *Specified Method* unless it is specifically identified as a *Specified Method* on the *Prohibited List*". As per the comment to the article, "the *Specified Substances* and *Methods* identified in Article 4.2.2 should not in any way be considered less important or less dangerous than other doping substances or methods. Rather, they are simply substances and methods which are more likely to have been consumed or used by an *Athlete* for a purpose other than the enhancement of sport performance."

Substances of Abuse

Pursuant to Article 4.2.3 of the Code, Substances of Abuse are substances that are identified as such because they are frequently abused in society outside of the context of sport. The following are designated Substances of Abuse: cocaine, diamorphine (heroin), methylenedioxymethamphetamine (MDMA/"ecstasy"), tetrahydrocannabinol (THC).

S0. NON-APPROVED SUBSTANCES

PROHIBITED AT ALL TIMES

(IN- AND OUT-OF-COMPETITION)

All prohibited substances in this class are *Specified Substances*

Any pharmacological substance which is not addressed by any of the subsequent sections of the *List* and with no current approval by any governmental regulatory health authority for human therapeutic use (e.g. drugs under pre-clinical or clinical development or discontinued, designer drugs, substances approved only for veterinary use) is prohibited at all times.

This class covers many different substances including but not limited to BPC-157.

S1. ANABOLIC AGENTS

PROHIBITED AT ALL TIMES

(IN- AND OUT-OF-COMPETITION)

All prohibited substances in this class are non-*Specified Substances*

Anabolic agents are prohibited.

1. ANABOLIC ANDROGENIC STEROIDS (AAS)

When administered exogenously, including but not limited to:

- 1-Androstenediol (5 α -androst-1-ene-3 β ,17 β -diol)
- 1-Androstenedione (5 α -androst-1-ene-3,17-dione)
- 1-Androsterone (3 α -hydroxy-5 α -androst-1-ene-17-one)
- 1-Epiandrosterone (3 β -hydroxy-5 α -androst-1-ene-17-one)
- 1-Testosterone (17 β -hydroxy-5 α -androst-1-en-3-one)
- 4-Androstenediol (androst-4-ene-3 β ,17 β -diol);
- 4-Hydroxytestosterone (4,17 β -dihydroxyandrost-4-en-3-one)
- 5-Androstenedione (androst-5-ene-3,17-dione)
- 7 α -hydroxy-DHEA
- 7 β -hydroxy-DHEA
- 7-Keto-DHEA
- 19-Norandrostenediol (estr-4-ene-3,17-diol)
- 19-Norandrostenedione (estr-4-ene-3,17-dione)
- Androstanolone (5 α -dihydrotestosterone, 17 β -hydroxy-5 α -androstan-3-one)
- Androstenediol (androst-5-ene-3 β ,17 β -diol)
- Androstenedione (androst-4-ene-3,17-dione)
- Bolasterone
- Boldenone
- Boldione (androsta-1,4-diene-3,17-dione)
- Calusterone
- Clostebol
- Danazol ([1,2]oxazololo[4',5':2,3]pregna-4-en-20-yn-17 α -ol)
- Dehydrochlormethyltestosterone (4-chloro-17 β -hydroxy-17 α -methylandrosta-1,4-dien-3-one)
- Desoxymethyltestosterone (17 α -methyl-5 α -androst-2-en-17 β -ol)

Drostanolone
 Epiandrosterone (3 β -hydroxy-5 α -androstan-17-one)
 Epi-dihydrotestosterone (17 β -hydroxy-5 β -androstan-3-one)
 Epitestosterone
 Ethylestrenol (19-norpregna-4-en-17 α -ol)
 Fluoxymesterone
 Formebolone
 Furazabol (17 α -methyl[1,2,5]oxadiazolo[3',4':2,3]-5 α -androstan-17 β -ol)
 Gestrinone
 Mestanolone
 Mesterolone
 Metandienone (17 β -hydroxy-17 α -methylandrosta-1,4-dien-3-one)
 Metenolone
 Methandriol
 Methasterone (17 β -hydroxy-2 α ,17 α -dimethyl-5 α -androstan-3-one)
 Methyl-1-testosterone (17 β -hydroxy-17 α -methyl-5 α -androstan-1-en-3-one)
 Methylclostebol
 Methylidienolone (17 β -hydroxy-17 α -methylestra-4,9-dien-3-one)
 Methylnortestosterone (17 β -hydroxy-17 α -methylestr-4-en-3-one)
 Methyltestosterone
 Metribolone (methyltrienolone, 17 β -hydroxy-17 α -methylestra-4,9,11-trien-3-one)
 Mibolerone
 Nandrolone (19-nortestosterone)
 Norboletone
 Norclostebol (4-chloro-17 β -ol-estr-4-en-3-one)
 Norethandrolone
 Oxabolone
 Oxandrolone
 Oxymesterone
 Oxymetholone
 Prasterone (dehydroepiandrosterone, DHEA, 3 β -hydroxyandrost-5-en-17-one)
 Prostanazol (17 β -[(tetrahydropyran-2-yl)oxy]-1'H-pyrazolo[3,4:2,3]-5 α -androstan-17-one)
 Quinbolone
 Stanozolol
 Stenbolone
 Testosterone
 Tetrahydrogestrinone (17 β -hydroxy-18 α -homo-19-nor-17 α -pregna-4,9,11-trien-3-one)
 Tibolone
 Trenbolone (17 β -hydroxyestr-4,9,11-trien-3-one)
 and other substances with a similar chemical structure or similar biological effect(s).

2. **OTHER ANABOLIC AGENTS**

Including, but not limited to:

Clenbuterol, osilodrostat, selective androgen receptor modulators [SARMs, e.g. andarine, enobosarm (ostarine), LGD-4033 (ligandrol) and RAD140], zeranol and zilpaterol.

S2. PEPTIDE HORMONES, GROWTH FACTORS, RELATED SUBSTANCES, AND MIMETICS

PROHIBITED AT ALL TIMES

(IN- AND OUT-OF-COMPETITION)

All prohibited substances in this class are non-*Specified Substances*

The following substances, and other substances with similar chemical structure or similar biological effect(s), are prohibited:

1. **ERYTHROPOIETINS (EPO) AND AGENTS AFFECTING ERYTHROPOIESIS**

Including, but not limited to:

- 1.1 Erythropoietin-receptor agonists, e.g. darbepoietin (dEPO); erythropoietins (EPO); EPO based constructs [e.g. EPO-Fc, methoxy polyethylene glycol-epoetin beta (CERA)]; EPO-mimetic agents and their constructs (e.g. CNTO 530, peginesatide).
- 1.2 Hypoxia-inducible factor (HIF) activating agents, e.g. cobalt; daprodustat (GSK1278863); IOX2; molindustat (BAY 85-3934); roxadustat (FG-4592); vadadustat (AKB-6548); xenon.
- 1.3 GATA inhibitors, e.g. K-11706.
- 1.4 Transforming growth factor beta (TGF- β) signalling inhibitors, e.g. luspatercept; sotatercept.
- 1.5 Innate repair receptor agonists, e.g. asialo EPO; carbamylated EPO (CEPO).

2. **PEPTIDE HORMONES AND THEIR RELEASING FACTORS**

- 2.1 Chorionic gonadotrophin (CG) and luteinizing hormone (LH) and their releasing factors in males, e.g. buserelin, deslorelin, gonadorelin, goserelin, leuprorelin, nafarelin and triptorelin.
 - 2.2 Corticotrophins and their releasing factors, e.g. corticorelin.
 - 2.3 Growth hormone (GH), its analogues and fragments including, but not limited to: growth hormone analogues, e.g. lonapegsomatropin, somapacitan and somatogon growth hormone fragments, e.g. AOD-9604 and hGH 176-191.
 - 2.4 Growth hormone releasing factors, including, but not limited to: growth hormone-releasing hormone (GHRH) and its analogues (e.g. CJC-1293, CJC-1295, sermorelin and tesamorelin) growth hormone secretagogues (GHS) and its mimetics [e.g. lenomorelin (ghrelin), anamorelin, ipamorelin, macimorelin and tabimorelin]; GH-releasing peptides (GHRPs) [e.g. alexamorelin, GHRP-1, GHRP-2 (pralmorelin), GHRP-3, GHRP-4, GHRP-5, GHRP-6, and examorelin (hexarelin)].
3. **GROWTH FACTORS AND GROWTH FACTOR MODULATORS**
Including, but not limited to:
Fibroblast growth factors (FGFs)
Hepatocyte growth factor (HGF)
Insulin-like growth factor-1 (IGF-1) and its analogues
Mechano growth factors (MGFs)
Platelet-Derived growth factor (PDGF)
Thymosin- β 4 and its derivatives e.g. TB-500
Vascular-endothelial growth factor (VEGF)

and other growth factors or growth factor modulators affecting muscle, tendon or ligament protein synthesis/ degradation, vascularisation, energy utilization, regenerative capacity or fibre type switching.

S3. BETA-2 AGONISTS

PROHIBITED AT ALL TIMES

(IN- AND OUT-OF-COMPETITION)

All prohibited substances in this class are *Specified Substances*

All selective and non-selective beta-2 agonists, including all optical isomers, are prohibited.

Including, but not limited to:

Arformoterol
Fenoterol
Formoterol
Higenamine
Indacaterol
Levosalbutamol
Olodaterol
Procaterol
Reproterol
Salbutamol
Salmeterol
Terbutaline
Tretoquinol (trimetoquinol)
Tulobuterol
Vilanterol

Exceptions

- Inhaled salbutamol: maximum 1600 micrograms over 24 hours in divided doses not to exceed 600 micrograms over 8 hours starting from any dose;
- Inhaled formoterol: maximum delivered dose 54 micrograms over 24 hours;
- Inhaled salmeterol: maximum 200 micrograms over 24 hours.
- Inhaled vilanterol: maximum 25 micrograms over 24 hours.

Note

The presence in urine of salbutamol in excess of 1000 ng/mL or formoterol in excess of 40 ng/mL is not consistent with therapeutic use of the substance and will be considered as an *Adverse Analytical Finding (AAF)* unless the *Athlete* proves, through a controlled pharmacokinetic study, that the abnormal result was the consequence of a therapeutic dose (by inhalation) up to the maximum dose indicated above.

S4. HORMONE AND METABOLIC MODULATORS

PROHIBITED AT ALL TIMES

(IN- AND OUT-OF-COMPETITION)

Prohibited substances in classes S4.1 and S4.2 are *Specified Substances*. Those in classes S4.3 and S4.4 are *non-Specified Substances*.

The following hormone and metabolic modulators are prohibited:

1. **AROMATASE INHIBITORS**

Including, but not limited to:

- 2-Androstenol (5 α -androst-2-en-17-ol)
- 2-Androstenone (5 α -androst-2-en-17-one)
- 3-Androstenol (5 α -androst-3-en-17-ol)
- 3-Androstenone (5 α -androst-3-en-17-one)
- 4-Androstene-3,6,17 trione (6-oxo)
- Aminoglutethimide
- Anastrozole
- Androsta-1,4,6-triene-3,17-dione (androstatrienedione)
- Androsta-3,5-diene-7,17-dione (arimistane)
- Exemestane
- Formestane
- Letrozole
- Testolactone

2. **ANTI-ESTROGENIC SUBSTANCES [ANTI-ESTROGENS AND SELECTIVE ESTROGEN RECEPTOR MODULATORS (SERMS)]**

Including, but not limited to:

- Bazedoxifene
- Clomifene
- Cyclofenil
- Fulvestrant
- Ospemifene
- Raloxifene
- Tamoxifen
- Toremifene

3. **AGENTS PREVENTING ACTIVIN RECEPTOR IIB ACTIVATION**

Including, but not limited, to:

- Activin A-neutralising antibodies;
- Activin receptor IIB competitors such as:
 - Decoy activin receptors (e.g. ACE-031);
- Anti-activin receptor IIB antibodies (e.g. bimagrumb);
- Myostatin inhibitors such as:
 - Agents reducing or ablating myostatin expression
 - Myostatin-binding proteins (e.g. follistatin, myostatin propeptide)
 - Myostatin-neutralising antibodies (e.g. domagrozumab, landogrozumab, stamulumab)

4. **METABOLIC MODULATORS**

- 4.1 Activators of the AMP-activated protein kinase (AMPK), e.g. AICAR, SR9009; and peroxisome proliferator activated receptor δ (PPAR δ) agonists, e.g. 2-(2-methyl-4-((4-methyl-2-(4-(trifluoromethyl)phenyl)thiazol-5-yl)methylthio)phenoxy) acetic acid (GW1516, GW501516)
- 4.2 Insulins and insulin-mimetics
- 4.3 Meldonium
- 4.4 Trimetazidine

S5. DIURETICS AND MASKING AGENTS

PROHIBITED AT ALL TIMES

(IN- AND OUT-OF-COMPETITION)

All prohibited substances in this class are *Specified Substances*

The following diuretics and masking agents are prohibited, as are other substances with a similar chemical structure or similar biological effect(s).

Including, but not limited to:

- Desmopressin; probenecid; plasma expanders, e.g. intravenous administration of albumin, dextran, hydroxyethyl starch and mannitol.
- Acetazolamide; amiloride; bumetanide; canrenone; chlortalidon; etacrynic acid; furosemide; indapamide; metolazone; spironolactone; thiazides, e.g. bendroflumethiazide, chlorothiazide; and hydrochlorothiazide; triamterene and vaptans, e.g. tolvaptan.

Exceptions

- Drospirenone; pamabrom; and topical ophthalmic administration of carbonic anhydrase inhibitors (e.g. dorzolamide, brinzolamide).
- Local administration of felypressin in dental anaesthesia.

Note

The detection in an *Athlete's Sample* at all times or *In-Competition*, as applicable, of any quantity of the following substances subject to threshold limits: formoterol, salbutamol, cathine, ephedrine, methylephedrine and pseudoephedrine, in conjunction with a diuretic or masking agent, will be considered as an *Adverse Analytical Finding (AAF)* unless the *Athlete* has an approved *Therapeutic Use Exemption (TUE)* for that substance in addition to the one granted for the diuretic or masking agent.

PROHIBITED METHODS

PROHIBITED AT ALL TIMES

(IN- AND OUT-OF-COMPETITION)

All prohibited methods in this class are non-*Specified* except methods in M2.2. which are *Specified Methods*.

M1. MANIPULATION OF BLOOD AND BLOOD COMPONENTS

The following are prohibited:

1. The *Administration* or reintroduction of any quantity of autologous, allogenic (homologous) or heterologous blood, or red blood cell products of any origin into the circulatory system.
2. Artificially enhancing the uptake, transport or delivery of oxygen.
Including, but not limited to:
Perfluorochemicals; efaproxiral (RSR13) and modified haemoglobin products, e.g. haemoglobin-based blood substitutes and microencapsulated haemoglobin products, excluding supplemental oxygen by inhalation.
3. Any form of intravascular manipulation of the blood or blood components by physical or chemical means.

M2. CHEMICAL AND PHYSICAL MANIPULATION

The following are prohibited:

1. *Tampering, or Attempting to Tamper*, to alter the integrity and validity of *Samples* collected during *Doping Control*.
Including, but not limited to:
Sample substitution and/or adulteration, e.g. addition of proteases to *Samples*.
2. Intravenous infusions and/or injections of more than a total of 100 mL per 12-hour period except for those legitimately received in the course of hospital treatments, surgical procedures or clinical diagnostic investigations.

M3. GENE AND CELL DOPING

The following, with the potential to enhance sport performance, are prohibited:

1. The use of nucleic acids or nucleic acid analogues that may alter genome sequences and/or alter gene expression by any mechanism. This includes but is not limited to gene editing, gene silencing and gene transfer technology.
2. The use of normal or genetically modified cells.

S6. STIMULANTS

PROHIBITED IN-COMPETITION

All prohibited substances in this class are *Specified Substances* except those in S6.A, which are non-*Specified Substances*.

Substances of Abuse in this section: cocaine and methylenedioxymethamphetamine (MDMA /"ecstasy")

All stimulants, including all optical isomers, e.g. *d*- and *l*- where relevant, are prohibited.

Stimulants include:

A: NON-SPECIFIED STIMULANTS

Adrafinil
Amfepramone
Amfetamine
Amfetaminil
Amiphenazole
Benfluorex
Benzylpiperazine
Bromantan
Clobenzorex
Cocaine
Cropropamide
Crotetamide
Fencamine
Fenetylline
Fenfluramine
Fenproporex
Fonturacetam [4-phenylpiracetam (carphedon)]
Furfenorex
Lisdexamfetamine
Mefenorex
Mephentermine
Mesocarb
Metamfetamine(*d*-)
p-methylamphetamine
Modafinil
Norfenfluramine
Phendimetrazine
Phentermine
Prenylamine
Prolintane

A stimulant not expressly listed in this section is a *Specified Substance*.

B: SPECIFIED STIMULANTS

Including, but not limited to:

3-Methylhexan-2-amine (1,2-dimethylpentylamine)
4-fluoromethylphenidate
4-Methylhexan-2-amine (methylhexaneamine)
4-Methylpentan-2-amine (1,3-dimethylbutylamine)
5-Methylhexan-2-amine (1,4-dimethylpentylamine)
Benzfetamine
Cathine²⁾
Cathinone and its analogues, e.g. mephedrone, methedrone, and α -pyrrolidinovalerophenone
Dimetamfetamine (dimethylamphetamine)
Ephedrine³⁾
Epinephrine⁴⁾ (adrenaline)
Etamivan
Ethylphenidate
Etilamfetamine
Etilefrine
Famprofazone
Fenbutrazate
Fencamfamin
Heptaminol
Hydrafinil (fluorenol)
Hydroxyamfetamine (parahydroxyamphetamine)
Isometheptene
Levmetamfetamine

²⁾ Cathine (*d*-norpseudoephedrine) and its *l*-isomer: Prohibited when its concentration in urine is greater than 5 micrograms per millilitre.

³⁾ Ephedrine and methylephedrine: Prohibited when the concentration of either in urine is greater than 10 micrograms per milliliter.

⁴⁾ Epinephrine (adrenaline): Not prohibited in local administration, e.g. nasal, ophthalmologic, or co-administration with local anaesthetic agents.

Meclofenoxate
Methylenedioxyamphetamine
Methylephedrine⁵⁾
Methylnaphthidate [((±)-methyl-2-(naphthalen-2-yl)-2-(piperidin-2-yl)acetate]
Methylphenidate
Nikethamide
Norfenefrine
Octodrine (1,5-dimethylhexylamine)
Octopamine
Oxilofrine (methylnephrine)
Pemoline
Pentetrazol
Phenethylamine and its derivatives
Phenmetrazine
Phenpromethamine
Propylhexedrine
Pseudoephedrine⁶⁾
Selegiline
Sibutramine
Strychnine
Tenamfetamine (methylenedioxyamphetamine)
Tuaminoheptane
and other substances with a similar chemical structure or similar biological effect(s).

Exceptions

- Clonidine;
- Imidazoline derivatives for dermatological, nasal or ophthalmic use (e.g. brimonidine, clonazoline, fenoxazoline, indanazoline, naphazoline, oxymetazoline, xylometazoline) and those stimulants included in the 2022 Monitoring Program⁷⁾.

S7. NARCOTICS

PROHIBITED IN-COMPETITION

All prohibited substances in this class are *Specified Substances*.

Substance of Abuse in this section: diamorphine (heroin)

The following narcotics, including all optical isomers, e.g. *d*- and *l*- where relevant, are prohibited.

Buprenorphine
Dextromoramide
Diamorphine (heroin)
Fentanyl and its derivatives
Hydromorphone
Methadone
Morphine
Nicomorphine
Oxycodone
Oxymorphone
Pentazocine
Pethidine

⁵⁾ Ephedrine and methylephedrine: Prohibited when the concentration of either in urine is greater than 10 micrograms per milliliter.

⁶⁾ Pseudoephedrine: Prohibited when its concentration in urine is greater than 150 micrograms per millilitre.

⁷⁾ Bupropion, caffeine, nicotine, phenylephrine, phenylpropanolamine, pipradrol, and synephrine: These substances are included in the 2022 Monitoring Program, and are not considered *Prohibited Substances*.

S8. CANNABINOIDS

PROHIBITED IN-COMPETITION

All prohibited substances in this class are *Specified Substances*.

Substance of Abuse in this section: tetrahydrocannabinol (THC)

All natural and synthetic cannabinoids are prohibited, e.g.:

- In cannabis (hashish, marijuana) and cannabis products
- Natural and synthetic tetrahydrocannabinols (THCs)
- Synthetic cannabinoids that mimic the effects of THC

Exceptions

- Cannabidiol.

S9. GLUCOCORTICOIDS

PROHIBITED IN-COMPETITION

All prohibited substances in this class are *Specified Substances*.

All glucocorticoids are prohibited when administered by any injectable, oral [including oromucosal (e.g. buccal, gingival, sublingual)] or rectal route.

Including but not limited to:

Beclometasone
Betamethasone
Budesonide
Ciclesonide
Cortisone
Deflazacort
Dexamethasone
Flucortolone
Flunisolide
Fluticasone
Hydrocortisone
Methylprednisolone
Mometasone
Prednisolone
Prednisone
Triamcinolone acetonide

Note

Other routes of administration (including inhaled, and topical: dental-intracanal, dermal, intranasal, ophthalmological and perianal) are not prohibited when used within the manufacturer's licensed doses and therapeutic indications.

P1. BETA-BLOCKERS

PROHIBITED IN PARTICULAR SPORTS

All prohibited substances in this class are *Specified Substances*

Beta-blockers are prohibited *In-Competition* only, in the following sports, and also prohibited *Out-of-Competition* where indicated (*).

- Archery (WA)⁸⁾
- Automobile (FIA)
- Billiards (all disciplines) (WCBS)
- Darts (WDF)
- Golf (IGF)

⁸⁾ Also prohibited *Out-of-Competition*

- Shooting (ISSF, IPC)⁹⁾
- Skiing/Snowboarding (FIS) in ski jumping, freestyle aerials/halfpipe and snowboard halfpipe/big air
- Underwater sports (CMAS) in all subdisciplines of freediving, spearfishing and target shooting.

Including but not limited to:

Acebutolol
Alprenolol
Atenolol
Betaxolol;
Bisoprolol
Bunolol
Carteolol
Carvedilol
Celiprolol
Esmolol
Labetalol
Metipranolol;
Metoprolol
Nadolol
Nebivolol
Oxprenolol
Pindolol
Propranolol
Sotalol
Timolol

G. INWERKINGTREDING

De wijziging van 6 december 2021 van de Bijlage bij de Overeenkomst is op 1 januari 2022 in werking getreden voor alle partijen bij de Overeenkomst, waaronder het Koninkrijk der Nederlanden.

Wat betreft het Koninkrijk der Nederlanden, geldt de wijziging van de Bijlage, evenals de Overeenkomst, voor Nederland (het Europese deel en het Caribische deel), Curaçao en Sint Maarten.

In overeenstemming met artikel 19, tweede lid, van de Rijkswet goedkeuring en bekendmaking verdragen heeft de Minister van Buitenlandse Zaken bepaald dat de wijziging van 6 december 2021 van de Bijlage bij de Overeenkomst zal zijn bekendgemaakt in Nederland (het Europese deel en het Caribische deel), Curaçao en Sint Maarten op de dag na de datum van uitgifte van dit Tractatenblad.

Uitgegeven de *achttiende* januari 2022.

De Minister van Buitenlandse Zaken,

W.B. HOEKSTRA

⁹⁾ Also prohibited *Out-of-Competition*